Pharmafile Logo
Pharmafocus logo
Advanced Search

Spinraza

Showing 8 posts of 8 posts found.

Biogen unveils promising new data for Spinraza in pre-symptomatic infants with spinal muscular atrophy

July 2, 2019
Manufacturing and Production, Research and Development Biogen, Spinraza, pharma, spinal muscular atrophy

Biogen has introduced new data on the efficacy of Spinraza in the treatment of pre-symptomatic infants in spinal muscular atrophy …

News

NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza

May 15, 2019
Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy

NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

September 14, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, FDA, NICE, Novo Nordisk, Spinraza, brexit, bristol myers squibb, top 10

With the Pharmafocus team having avoided hurricane Florence and finally arriving back in the UK just last night, after stopping …

News

Protesters in Manchester call on NICE to approve Biogen’s $750,000 drug Spinraza

September 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Spinraza, approval, protest, sma

Protesters in Manchester have called on the National Institute of Health and Care Excellence (NICE), to overturn their rejection of …

News
biogen_austria_238

NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay

August 14, 2018
Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …

News
biogen_idec_hillerod_2008

Biogen boosts pipeline with $1bn Ionis deal

April 23, 2018
Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …

News
biogen_austria_238

Biogen’s Spinraza to go before NICE

January 22, 2018
Sales and Marketing Biogen, Spinraza, biotech, drugs, pharma, pharmaceutical

Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May …

News

EMA gives positive opinion on Biogen’s spinal muscular atrophy drug Spinraza

April 25, 2017
Manufacturing and Production, Sales and Marketing Biogen, Ionis, Spinraza, spinal muscular atrophy

Biogen has revealed that Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA) , has received a positive opinion from …

News

Latest content

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024